Vivos Therapeutics, Inc. — Form 8-K/A
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 28/100
What the filing says
Vivos Therapeutics filed an amended 8-K on 2026-09-08 for period ending 2026-09-02, reporting Items 1.01 (material definitive agreement entry) and 3.02 (unregistered equity sales). However, the actual agreement terms, counterparty identity, dollar amounts, share counts, and pricing are not disclosed in the filing metadata provided — only document structure and filing mechanics are visible.
Why this rating
Without concrete deal terms, counterparty, or amount details in the metadata, cannot assess materiality. If material agreement and equity raise are real, they could be significant to $22.9M company, but disclosure opacity prevents scoring higher.
Extracted items
- 1.01 material agreement
- 3.02
- 9.01 exhibits
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.